文献速递临床免疫临床微生物

快速床旁检测区分细菌与病毒感染的敏感性与特异性

Sensitivity and specificity of a rapid, point-of-care assay distinguishing bacterial from viral infections in acute care settings.
PubMed 文献 · J Clin Microbiol · 2026-10-27

本研究纳入203例急诊就诊事件,评估MeMed BV检测生成的0-100评分在区分细菌与病毒感染中的准确性,并与标准生物标志物及白细胞计数比较。结果显示,该检测「高细菌可能性」与「中细菌可能性」评分合计识别任何细菌感染的敏感性为87%、特异性为32%,识别菌血症的敏感性为95%、特异性为25%。研究表明,未按FDA批准情境使用该检测时无法充分发挥其效能。

要点

  • MeMed BV检测「高+中细菌可能性」评分识别任何细菌感染的敏感性87%、特异性32%。
  • 识别菌血症的敏感性95%、特异性25%。
  • 未按FDA批准情境使用该检测时无法充分发挥其效能。

核心结论

  • MeMed BV检测「高细菌可能性」与「中细菌可能性」评分合计识别任何细菌感染的敏感性为87%、特异性为32%,识别菌血症的敏感性为95%、特异性为25%。
  • 未按FDA批准情境使用该检测时无法充分发挥其效能。

研究设计与样本

  • 研究纳入203例疾病发作事件,其中108例与细菌感染相关(25例血培养阳性;107例非血液样本细菌病原体阳性),18例与病毒病原体相关。
  • 评估MeMed BV检测生成的0-100评分在急诊中帮助临床医生决定是否开具血培养的可行性,并评估其区分细菌与病毒感染的准确性。
  • 将该检测性能与标准生物标志物检测及白细胞计数预测细菌感染的能力进行比较。

主要发现

  • MeMed BV检测「高细菌可能性」与「中细菌可能性」评分合计识别任何细菌感染的敏感性为87%、特异性为32%。
  • 上述评分识别菌血症的敏感性为95%、特异性为25%。

关键数值与推荐

  • MeMed BV检测测量三种宿主免疫蛋白:肿瘤坏死因子相关凋亡诱导配体、干扰素γ诱导蛋白10和C反应蛋白,结果合并为0-100评分,评分越高提示细菌感染可能性越高,评分越低提示病毒感染或其他非细菌病因。

临床怎么用

  • MeMed BV检测可在急诊中辅助临床医生区分细菌与病毒感染,并帮助决定是否开具血培养。
  • 临床医生需正确开具和解读该检测结果,并应在FDA批准的情境下使用以充分发挥其效能。

局限性

  • 摘要未报告研究局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Differentiating between bacterial and viral infections is essential in the emergency department (ED) to guide appropriate antibiotic treatment. Recent assays, such as the Food and Drug Administration (FDA)-cleared MeMed BV assay, can help with this distinction. The MeMed BV assay measures three host immune proteins-Tumor necrosis factor (TNF)-related apoptosis-induced ligand, Interferon (IFN)-γ-induced protein 10, and C-reactive protein-in blood samples. The results are combined into a score from 0 to 100, where a higher score indicates a higher likelihood of a bacterial infection and a lower score suggests a viral infection or other non-bacterial causes. The study evaluates the feasibility of using the MeMed BV assay-generated score to help clinicians decide whether to order blood cultures in emergency departments, as well as assessing the accuracy of the MeMed BV assay in distinguishing between bacterial and viral infections in ED patients. The assay's performance was also compared with standard biomarker tests and white blood cell (WBC) counts for predicting bacterial infections. This study included 203 illness episodes, of which a total of 108 were associated with bacterial infection (25 had a positive blood culture; 107 had a non-blood sample positive for a bacterial pathogen) and 18 were associated with a viral pathogen. Combined, the MeMed BV assay's "high bacterial likelihood" and "moderate bacterial likelihood" scores yielded a sensitivity and specificity of 87% and 32%, respectively, in correctly identifying any bacterial infection; the scores had a sensitivity and specificity of 95% and 25%, respectively, in correctly identifying bacteremia. The future of differentiating between bacterial and viral infections is moving toward integrated diagnostic methods. To address antibiotic resistance, future diagnostics will leverage host immune response biomarkers, advanced molecular panels, and machine learning techniques. This will enable rapid and accurate results at the point of care. IMPORTANCE: Distinguishing between bacterial and viral infections in healthcare settings can be challenging, as patients often present with similar symptoms and clinical features. In recent years, several new biomarkers have emerged as promising targets for algorithm-based tests designed to differentiate between these types of infections. An increasing number of FDA-approved assays that utilize these biomarkers have entered the market, employing various algorithms. These tests are being used in different clinical settings, such as emergency rooms, to assist clinicians in making accurate diagnoses and prescribing antibiotics appropriately. It is essential for clinicians to correctly order and interpret the results of these assays to fully realize their potential. Our study demonstrates that when such an assay is not used within the FDA-approved context, it does not achieve its full effectiveness.

来源:J Clin Microbiol,查看原文。版权归原作者所有。

引用

  1. Sundaram ME, Wahlig TA, Arbefeville S, et al. Sensitivity and specificity of a rapid, point-of-care assay distinguishing bacterial from viral infections in acute care settings. J Clin Microbiol. 2026. PMID: 42937297. doi:10.1128/jcm.00262-26

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。